Huntington Beach, CANCT07024641Now EnrollingIRB Ready

Hepatitis B Virus Infection Clinical Trial in Huntington Beach, CA

Access cutting-edge hepatitis b virus infection treatment through this clinical trial at a research site in Huntington Beach. Study-provided care at no cost to qualified participants.

Sponsored by GigaGen, Inc.

Quick Self-Assessment

See if you qualify for this Huntington Beach location

Preparing your pre-screening questions…

Expert Care in Huntington Beach

Access hepatitis b virus infection specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hepatitis b virus infection treatment provided free

Apply for This Huntington Beach Location

Check if you qualify for this hepatitis b virus infection clinical trial in Huntington Beach, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Huntington Beach

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Huntington Beach site if eligible
  4. 4Begin participation

About This Hepatitis B Virus Infection Study in Huntington Beach

The primary purpose of this study is to assess the safety and tolerability of single and multiple intravenous (IV) doses of GIGA-2339 in participants with chronic Hepatitis B Virus (HBV) infection.

Sponsor: GigaGen, Inc.

Who Can Participate

Inclusion Criteria

Hepatitis B envelope antigen (HBeAg) negative chronic HBV infection for ≥ 6 months, defined as presence of Hepatitis B surface antigen (HBsAg) in serum for ≥ 6 months.
Serum HBsAg concentration between ≥ 100 international units per milliliter (IU/mL) and 2000 IU/mL at screening.
Currently on stable dose of nucleot(s)ide analogues (NAs) (≥ 6 months) and expected to continue while participating in the study, or are not received NAs.
Have serum HBV deoxyribonucleic acid (DNA) concentration ≤ 50 IU/mL at screening (for those who are on NAs); or have serum HBV DNA concentration ≤ 2000 IU/mL at screening (for those who are NOT on NAs).
Male participants must refrain from donating spermatozoa and agree to use highly effective contraception.
Female participants must not be pregnant, or breastfeeding; either should not be a woman of childbearing potential (WOCBP) or if WOCBP should use highly effective contraceptive methods. Key

Exclusion Criteria

Positive for co-infection with hepatitis C virus (HCV), human immunodeficiency virus (HIV), and/or hepatitis D virus (HDV) at screening.
Participants that weigh less than 50 kilograms (kg) and/or have a body mass index (BMI) less than 18.5.
History of documented liver cirrhosis at screening. Patients under liver cirrhosis evaluation at screening will not be eligible until cirrhosis is ruled out.
Liver stiffness \> 8 kilopascal (kPa) at screening.
History of chronic liver disease from another cause, immune complex disease, or autoimmune diseases that in the opinion of the investigator would preclude participation.
Family history of hepatocellular carcinoma (HCC).
Alpha fetoprotein \> 20 nanograms per milliliter (ng/mL).
Presence of a liver imaging reporting and data system (LI-RADS) 4 or 5 liver lesion on imaging 12 months prior to Screening OR, LI-RADS-US findings of US-3 grade on imaging 12 months prior to Screening, OR LIRADS-US grade 3 done prior to the D1 infusion visit, if prior LI-RADS or LI-RADS-US results are not available at Screening.
History of hematopoietic stem cell transplant or solid organ transplant.
Receipt of anti-HBV monoclonal antibody (mAb)/pAb therapy of any kind in the past (including hepatitis B immunoglobulin \[HBIG\]).
History of cardiovascular disease (e.g., coronary artery disease, cardiomyopathy, congestive heart failure, family history of congenital long QT syndrome). Stable hypertension is allowed.
Malignancy diagnosed and/or treated within 5 years prior to Screening, and/or with ongoing treatment for malignancy, with the exception of localized non-metastatic basal cell or squamous cell carcinoma of the skin or in-situ carcinoma of the cervix excised with curative intent.
Participants requiring anti-coagulation therapies (for example warfarin, Factor Xa inhibitors, or anti-platelet agents like clopidogrel).
Male participants with a corrected QT interval using Fridericia's formula (QTcF) \> 450 milliseconds (msec) and female participants with QTcF \> 470 msec on ECG recorded at screening. if the participant has evidence of an intraventricular conduction delay, defined as QRS interval greater than 110 msec, a QTcF is \> 500 msec for both males and females will be excluded.
Known hypersensitivity to any GIGA-2339 excipients or any confirmed significant allergic reactions (urticaria or anaphylaxis) against any drug, or multiple drug allergies (nonactive hay fever is acceptable), or a history of drug or other allergy that, in the opinion of the Investigator, contraindicates participation.
Received or will receive live-attenuated virus vaccinations such as measles, mumps, rubella or varicella within 4 weeks before and up to three months after administration of investigational product (IP).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Huntington Beach?

Yes, this clinical trial (NCT07024641) has an active research site in Huntington Beach, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hepatitis B Virus Infection Treatment Options in Huntington Beach, CA

If you're searching for hepatitis b virus infection treatment options in Huntington Beach, CA, this clinical trial (NCT07024641) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Huntington Beach research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hepatitis b virus infection specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hepatitis b virus infection clinical trials near you to find additional studies recruiting in your area.

More Hepatitis B Trials in Huntington Beach, CA

See all hepatitis b clinical trials recruiting in Huntington Beach — not just this study.

Browse Hepatitis B Trials in Huntington Beach →

Browse More Trials by Condition

Hepatitis B TrialsAll Conditions →

Ready to Join in Huntington Beach?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Huntington Beach, CA